Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005227235
Fri, 15.11.2024
Biotest AG
PRESS RELEASE
Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations
Plasma donation centers in Europe to secure the long-term supply of plasma
Dreieich, Germany, November 15, 2024. Darmstadt's most modern blood plasma donation center in the TOWN HOUSE in the forme [ … ]
Thu, 14.11.2024
Biotest AG
PRESS RELEASE
Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million
Product sales and toll manufacturing increased by 13,7% to € 414 million, in part thanks to the growth of Yimmugo®
Adjusted EBIT was maintained at previous year's level as growing core business gradually replaces earnings from technology transfer and [ … ]
Thu, 14.11.2024
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged
Dreieich, Germany, November 14, 2024. The Board of Management currently expects a revenue increase in the low single-digit percentage range for the 2024 financial year compare [ … ]
Tue, 29.10.2024
Biotest AG
PRESS RELEASE
Biotest and SteinCares partner to improve access to plasma-derived products in Latin America
Financial and strategic reliability is key driver of partnership to start to penetrate Latin American markets with plasma-derived Factor VIII products
Agreement will be the first step to its expand our commercial footprint in the are [ … ]
Wed, 02.10.2024
Biotest AG
PRESS RELEASE
Strategic agreement signed for distribution of Yimmugo® in the United States based on the framework established in July
All contractual terms finalized and definitive agreement with Kedrion signed
Expected to generate revenues of more than $1 billion for Biotest during the 7-year term
Preparations for U.S. launch of [ … ]
Thu, 12.09.2024
Biotest AG
PRESS RELEASE
Change in the Chief Financial Officer at Biotest AG
Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14
Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal [ … ]
Thu, 12.09.2024
Biotest AG
PRESS RELEASE
Change in the Chief Financial Officer at Biotest AG
Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14
Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal [ … ]
Thu, 05.09.2024
Biotest AG
PRESS RELEASE
Biotest AG opens 13th plasma collection center in Germany
39 plasma collection centers in Europe to ensure long-term plasma supply
Dreieich, Germany, September 5, 2024. Biotest has officially opened its 13th plasma collection center in Germany in Karlsruhe. In the state-of-the-art center at Europaplatz in Kaiserstra [ … ]
Wed, 28.08.2024
Biotest AG
PRESS RELEASE
Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG
Dreieich, Germany, August 28, 2024. Biotest AG announced today that Dr. Jörg Schüttrumpf will in future focus on his role as Chief Scientific Innovation Officer of the entire Grifols Group. He will therefore resign from his position as Chief Sci [ … ]
Tue, 06.08.2024
Biotest AG
PRESS RELEASE
Biotest increases sales in the first half of 2024 by 35% to €372 million
EBIT increased to €78.4 million
FDA approval of Yimmugo® received in June 2024
FDA certification of the BNL production facility in Dreieich
Dreieich, 06 August 2024. In the first half of the 2024 financial year, the Biotest Group generated revenue [ … ]